Press releaseBusiness Wire
Faeth Therapeutics
FTH · NASDAQ
$20.79+$1.35 (+6.94%)TodayMarket closed ·
Prev close $19.44
Latest news
- Press releaseBusiness Wire
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
- Press releaseBusiness Wire
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
- Press releaseBusiness Wire
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
- Press releaseBusiness Wire
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releaseBusiness Wire
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
- Press releaseBusiness Wire
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
- Press releaseBusiness Wire
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releaseBusiness Wire
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
- Press releaseBusiness Wire
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releaseBusiness Wire
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releaseBusiness Wire
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releaseBusiness Wire
Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.